• Stephen A. Brunton
  • Rita K. Edwards


Despite widespread efforts to improve education and enhance public awareness, up to 33% of persons with hypertension remain undiagnosed, and only about 50% of those known to have hypertension are adequately controlled. The percentages of patients who are aware that they have hypertension, who are treated, and who are controlled have increased since the 1970s (Table 75.1). Most have stage 1 hypertension, and controversy still exists concerning the appropriate approach to these patients. Nonpharmacologic therapy is often the first choice, and this approach continues to evolve.1 Of the 20 million to 30 million hypertensives who receive pharmacologic therapy, fewer than 50% adhere to their therapeutic regimen for more than 1 year, and 60% of these patients reduce the dosage of their drug owing to adverse effects. A negative impact on the patient’s quality of life may occur as a result of just making the diagnosis.


Peripheral Vascular Disease Adverse Effect Profile Joint National Committee Angiotensin Receptor Antagonist Intrinsic Sympathomimetic Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    National Institutes of Health. Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education. Bethesda: National Heart, Lung and Blood Institute, 1993. NIH Publication No. 93–1088.Google Scholar
  2. 2.
    Haynes RB, Sackett DL, Taylor DW, et al. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978;297:741–4.CrossRefGoogle Scholar
  3. 3.
    Gordon T, Doyle JT. Alcohol consumption and its relationship to smoking, weight, blood pressure, and blood lipids. Arch Intern Med 1986;146:262–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events. J Chronic Dis 1978;31:201–6.CrossRefGoogle Scholar
  5. 5.
    Stamler J, Farinaro E, Majonnier LM, et al. Prevention and control of hypertension by nutritional-hygienic means. JAMA 1980;243:1819–23.PubMedCrossRefGoogle Scholar
  6. 6.
    Rose G, Stamler J. The Intersalt Study: background, methods and main results; Intersalt Cooperative Research Group. J Hum Hypertens 1989;3:283–8.PubMedGoogle Scholar
  7. 7.
    Cade R, Mars D, Wagemaker H, et al. Effect of aerobic exercise training on patients with systemic arterial hypertension. Am J Med 1984;77:785–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Margetts BM, Beilin LJ, Armstrong BK. A randomized control trial of a vegetarian diet in the treatment of mild hypertension. Clin Exp Pharmacol Physiol 1985;12:263–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaplan NM. Non-drug treatment of hypertension. Ann Intern Med 1985;102:359–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Witteman JC, Willett WC, Stampfer MJ, et al. A prospective study of nutritional factors and hypertension among US women. Circulation 1989;80:1320–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Patel C, Marmot MG. Stress management, blood pressure and quality of life. J Hypertens 1987;5 Suppl 1:521–8.Google Scholar
  12. 12.
    Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure. JAMA 1987;257:1484–91.PubMedCrossRefGoogle Scholar
  13. 13.
    American Hospital Formulary Service Drug Information. Bethesda: American Society of Hospital Pharmacists, 1990.Google Scholar
  14. 14.
    Kaplan NM. Clinical hypertension. 5th ed. Baltimore: Williams & Wilkins, 1993.Google Scholar
  15. 15.
    Houston MC. New insights and new approaches for the treatment of essential hypertension: selection of therapy based on coronary heart disease, risk factor analysis, hemodynamic profiles, quality of life and subsets of hypertension. Am Heart J 1989;117:911–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Merck and Co. Cozaar monograph. Rahway, NJ: Merck, April 1995.Google Scholar
  17. 17.
    Jachuck SJ, Brierly H, Jachuck S, et al. The effect of hypotensive drugs on quality of life. J R Coll Gen Pract 1982;32:103–5.PubMedGoogle Scholar
  18. 18.
    Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314:1657–64.PubMedCrossRefGoogle Scholar
  19. 19.
    Steiner SS, Friedhoff AJ, Wilson BL, et al. Antihypertensive therapy and quality of life: a comparison of atenolol, captopril, enalapril and propranolol. J Hum Hypertens 1990;4:217–25.PubMedGoogle Scholar
  20. 20.
    Furberg CD, Psaty BM, Meyer JV. Nifedipine, dose related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326–31.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Stephen A. Brunton
  • Rita K. Edwards

There are no affiliations available

Personalised recommendations